# US 2019/0167723 A1 · Serum fraction of platelet-rich fibrin as a cell culture additive

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167723 A1
- Document ID: US20190167723A1
- Status: Published application
- Kind: A1
- Application number: 16/173,430
- Filed: 2018-10-29
- Published: 2019-06-06
- Earliest claimed: 2013-02-12
- Assignees: Lacerta Technologies Inc.
- Applicants: Lacerta Technologies Inc.
- Inventors: Zsombor LACZA; Gabriella VÁCZ; István HORNYÁK; Melinda SIMON; Olga KUTÉN; Vivek JEYAKUMAR
- Web page: https://patentgrep.com/patent/US20190167723A1

## CPC

- A61K 35/19: Platelets; Megacaryocytes
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61K 38/018: {from milk}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61L 27/3616: {Blood, e.g. platelet-rich plasma}
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 27/3817: {Cartilage-forming cells, e.g. pre-chondrocytes}
- A61L 27/52: Hydrogels or hydrocolloids
- C12N 5/0655: {Chondrocytes; Cartilage}
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- C12N 2533/56: Fibrin; Thrombin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of preparing an isolated serum fraction of platelet rich fibrin, cell cultures comprising said serum fraction and its use as a cell culture additive. The invention also relates to increasing proliferation rate of chondrocytes, to the treatment of articular or joint diseases and to increasing the proliferation rate of mesenchymal stem cells. The isolated serum fraction of platelet rich fibrin (PRF), is prepared by providing platelet rich plasma (PRP) without the addition of an anticoagulant; clotting the PRP to obtain a coagel of PRF; and separating the coagel to isolate the serum fraction which comprises an activated platelet releasate; and further provides for the isolated serum fraction obtained by such method, and its medical use.

## Claims

### Claim 1

A cell culture comprising
mammalian cells,
a cell culture medium,
a serum fraction containing the fluid fraction of platelet-rich fibrin, i.e. serum fraction of PRF (SPRF),
wherein
said SPRF being obtained by a method comprising the steps of
a. separating and removing the red blood cell fraction from a venous blood sample to provide a plasma without the addition of an anticoagulant;
b. clotting said plasma to obtain a coagel of PRF spontaneously by centrifugation carried out at 1000 to 5000 g and a supernatant, wherein in said method the centrifugation is carried out for 2 to 20 minutes;
c. pressing or squeezing the coagel to obtain fluid fraction from the coagel, thereby obtaining said SPRF;
wherein said SPRF is added to the medium,
said SPRF comprising a platelet releasate from activated platelets and
said SPRF comprising a reduced content of red blood cells, platelets or fibrinogen as compared to whole blood or a reduced content of fibrin as compared to said plasma, and
wherein said SPRF is capable of inducing cell proliferation or restoring cell proliferation capacities.

### Claim 2 (depends on 1)

The cell culture of claim 1 wherein said cell culture
does not comprise fetal bovine serum (FBS) or fetal calf serum (FCS), and does not comprise platelet rich plasma (PRP) and does not comprise any other growth factor either, only those which are present in the SPRF.

### Claim 3 (depends on 1)

The cell culture according to claim 1 wherein said SPRF is depleted in a growth factor selected from the group consisting of PDGF-AB, PDGF-BB and TGF beta-1
as compared to platelet rich plasma (PRP).

### Claim 4 (depends on 1)

The cell culture according to claim 1 wherein said cells are mammalian cells.

### Claim 5 (depends on 4)

The cell culture according to claim 4 wherein said mammalian cells are selected from the group consisting of stem cells, epithelial cells, cells of the periosteum, osteogenic cells, angiogenic cells, stromal cells, mesenchymal cells, e.g. mesenchymal cells of bone marrow, adipose tissue, microvascular tissue or other mesenchymal tissue origin, osteoprogenitor cells and bone cells.

### Claim 6 (depends on 1)

The cell culture of claim 1 wherein in said cell culture the SPRF is prepared by a method
wherein centrifugation is carried out at 1000 to 2000 g.

### Claim 7 (depends on 1)

The cell culture of claim 1 wherein
said medium comprises 2-20% (v/v), preferably 5-15% (v/v), highly preferably 8 to 12% (v/v) or about 10% (v/v) SPRF and
wherein said medium comprises besides SPRF, no FBS (FCS) and no other serum derived product or supplement and preferably no other growth factors.

### Claim 8 (depends on 7)

The cell culture of claim 7 wherein
the medium is a derivative of Dulbecco's modified Eagle's medium (DMEM) which differs from DMEM in that it is supplemented with 2-20% (v/v), preferably 5-15% (v/v), highly preferably with 8 to 12% (v/v) or about 10% (v/v) SPRF and comprises no other serum derived product or supplement and no other growth factors.

### Claim 9 (depends on 7)

The cell culture of claim 7 wherein
the cells in the culture are MSCs that are contacted or maintained in contact with SPRF, preferably for until at least a time-period when osteoblast direction differentiation occurs, preferably for until at least a time-period when the expression of at least one, preferably two or at least two osteoblast specific marker gene(s) is/are increased in a medium supplemented with SPRF.

### Claim 10 (depends on 7)

The cell culture of claim 7 wherein
the cells are chondrocytes and
SPRF is added to the culturing medium of chondrocytes.

### Claim 11

A method for using an isolated serum fraction of platelet rich fibrin (SPRF) as a cell culture additive, said method comprising the steps of
culturing cells by incubating said cells in a medium, and
adding the SPRF to the medium,
said SPRF being obtained by a method comprising the steps of
a. separating and removing the red blood cell fraction from a venous blood sample without the addition of an anticoagulant, to provide a plasma;
b. clotting said plasma to obtain a coagel of PRF spontaneously by centrifugation carried out at 1000 to 5000 g and a supernatant, wherein in said method the centrifugation is carried out for 2 to 20 minutes;
c. pressing or squeezing the coagel to obtain fluid fraction from the coagel, thereby obtaining said SPRF;
said SPRF comprising a platelet releasate from activated platelets and
said SPRF comprising a reduced content of red blood cells, platelets or fibrinogen as compared to whole blood or a reduced content of fibrin as compared to said plasma, and
wherein said SPRF is capable of inducing cell proliferation or restoring cell proliferation capacities.

### Claim 12 (depends on 11)

The method of claim 11 for using an isolated serum fraction of platelet rich fibrin (SPRF) as
a cell culture additive, said method comprising the steps of
contacting the isolated serum fraction with a culture of cells in vitro,
incubating said cells in vitro for a period of time sufficient to promote cell growth or regeneration,
thereby promoting proliferation of cells.

### Claim 13 (depends on 11)

The method of claim 11 wherein said medium or said cell culture
does not comprise fetal bovine serum (FBS) or fetal calf serum (FCS), and does not comprise platelet rich plasma (PRP) and does not comprise any other growth factor either, only those which are present in the SPRF,
wherein said SPRF enhances the proliferation rate of said cells in vitro, ex vivo or in vivo, while maintaining their potential to differentiate into several cell types.

### Claim 14 (depends on 11)

The method according to claim 11 wherein said isolated serum fraction is depleted in a growth factor selected from the group consisting of PDGF-AB, PDGF-BB and TGF beta-1
as compared to said plasma or whole blood.

### Claim 15 (depends on 11)

The method according to claim 11 wherein said cells are mammalian cells.

### Claim 16 (depends on 15)

The method according to claim 15 wherein said mammalian cells are selected from the group consisting of stem cells, epithelial cells, cells of the periosteum, osteogenic cells, angiogenic cells, stromal cells, mesenchymal cells of bone marrow, adipose tissue, microvascular tissue or other mesenchymal tissue origin, osteoprogenitor cells, bone cells and chondrocytes.

### Claim 17 (depends on 11)

The method according to claim 11 wherein the serum fraction is freshly prepared and ready-for-use.

### Claim 18 (depends on 11)

The method according to claim 11 wherein the serum fraction is provided in an application device.

### Claim 19 (depends on 11)

The method according to claim 11 wherein the serum fraction is prepared as an autologous pharmaceutical or medicinal product.

### Claim 20 (depends on 11)

The method according to claim 11, wherein the cells in the medium comprising SPRF as a cell culture additive are administered to a patient.

### Claim 21 (depends on 11)

The method according to claim 11 for increasing proliferation rate of dedifferentiated chondrocytes comprising contacting a serum fraction of platelet rich fibrin (SPRF) with dedifferentiated chondrocytes, said SPRF being prepared from whole blood obtained from one or more donor subject(s).

### Claim 22 (depends on 11)

The method according to claim 11 wherein SPRF does not redifferentiate chondrocytes from the dedifferentiated state or provides a lesser extent of redifferentiation than PRP, preferably measured by the col II/col I ratio.

### Claim 23 (depends on 11)

The method according to claim 11 wherein SPRF obtained from a donor subject is used for increasing proliferation rate of chondrocytes in vitro before transplantation thereof, wherein preferably SPRF is applied in the cell culture in a concentration between 1-25% or 2-20%, preferably 5 to 15%, highly preferably 8 to 12% or in particular about 10%, wherein the percentage of concentration is given in v/v %.

### Claim 24 (depends on 11)

The method according to claim 11 wherein said method is a method of transplantation or implantation of chondrocytes into a patient in need thereof, wherein said SPRF is an SPRF prepared from whole blood obtained from a donor subject and wherein said SPRF is contacted with the dedifferentiated chondrocytes to be transplanted or implanted to said patient in vitro, to use for increasing proliferation rate of said chondrocytes.

### Claim 25 (depends on 24)

The method according to claim 24 wherein the patient is a subject in need of cartilage repair, in particular articular cartilage repair and/or cartilage replacement therapy, preferably articular cartilage repair,
or in more particular the patient is a subject with cartilage failure, osteoarthritis, cartilage damage, osteochondral damage, rheumatoid arthritic damage, autoimmune arthritis, reactive arthritis,
cellular matrix linkage rupture, chondrocyte protein synthesis inhibition, and chondrocyte apoptosis, a condition requiring cartilage regeneration in particular in cartilage ulcer, osteoarthritis or traumatic cartilage loss, a condition requiring subchondral bone regeneration in osteoarthritis, Ahlback's disease or osteochondral lesions.

### Claim 26 (depends on 11)

The method according to claim 11 for use of serum fraction of platelet rich fibrin (SPRF) for selectively increasing MSC proliferation rate in vitro, in vivo or ex vivo wherein said differentiated MSCs maintain their potential to differentiate into several cell types, preferably MSCs are obtained from a subject.

### Claim 27 (depends on 26)

The method according to claim 26, said method comprising
i. providing SPRF,
ii. adding SPRF to a pool of MSCs,
iii. allowing MSCs to proliferate,
for at least 5 days.

### Claim 28 (depends on 26)

The method according to claim 26 for use of SPRF as a cell medium supplement instead of PRP and FBS wherein said SPRF enhances the proliferation rate of human mesenchymal stem cells in vitro, ex vivo or in vivo, while maintaining their potential to differentiate into several cell types, wherein upon proliferation of MSCs expression of one or both of the following osteogenic marker genes is increased: COL1A1 and ALPL, and wherein
said medium comprises SPRF, preferably 2-20% (v/v), preferably 5-15% (v/v), highly preferably 8 to 12% (v/v) or about 10% (v/v) SPRF, as a supplement and
the medium does not comprise fetal bovine serum (FBS) or fetal calf serum (FCS), and does not comprise platelet rich plasma (PRP) and preferably does not comprise FGF (e.g. bFGF) and preferably does not comprise any other growth factor either, only those which are present in the SPRF.

### Claim 29 (depends on 26)

The method according to claim 26 for use of SPRF in therapy, preferably in stem cell therapy, wherein in said therapy SPRF obtained from a donor subject is used to increase proliferation rate of the patient's MSCs expanded in vitro, ex vivo or in vivo, wherein the MSCs so proliferated maintain their undifferentiated character with the potential to differentiate into several cell types,
wherein proliferation of MSCs is carried out for at least 5 days.

### Claim 30 (depends on 26)

The method according to claim 26 wherein the MSCs are bone marrow derived mesenchymal stem cells (BM-MSCs or bone marrow stromal stem cells), or
the MSCs are adipose derived mesenchymal stem cells (AD-MSCs), wherein
preferably the MSC culturing medium normally comprises a carbon source, preferably a sugar source and preferably a glutamine source and preferably pyruvate.

### Claim 31

A medium comprising
a cell culture medium and
a serum fraction containing the fluid fraction of platelet-rich fibrin, i.e. serum fraction of PRF (SPRF),
wherein
said SPRF being obtained by a method comprising the steps of
a. separating and removing the red blood cell fraction from a venous blood sample to provide a plasma without the addition of an anticoagulant;
b. clotting said plasma to obtain a coagel of PRF spontaneously by centrifugation carried out at 1000 to 5000 g and a supernatant, wherein in said method the centrifugation is carried out for 2 to 20 minutes;
c. pressing or squeezing the coagel to obtain fluid fraction from the coagel, thereby obtaining said SPRF;
wherein said SPRF is added to the cell culture medium,
said SPRF comprising a platelet releasate from activated platelets and
said SPRF comprising a reduced content of red blood cells, platelets or fibrinogen as compared to whole blood or a reduced content of fibrin as compared to said plasma, and
wherein said SPRF is capable of inducing cell proliferation or restoring cell proliferation capacities.

### Claim 32 (depends on 31)

The medium, according to claim 31 wherein said cell culture medium
does not comprise fetal bovine serum (FBS) or fetal calf serum (FCS), and does not comprise platelet rich plasma (PRP) and does not comprise any other growth factor either, only those which are present in the SPRF.

### Claim 33 (depends on 31)

The medium according to claim 31 wherein said isolated SPRF is depleted in a growth factor selected from the group consisting of PDGF-AB, PDGF-BB and TGF beta-1
as compared to platelet rich plasma (PRP).

### Claim 34 (depends on 31)

The medium according to claim 31 wherein said cell culture medium is a stem cell culture medium.

### Claim 35 (depends on 31)

The medium according to claim 31 wherein said mammalian cells are selected from the group consisting of stem cells, epithelial cells, cells of the periosteum, osteogenic cells, angiogenic cells, stromal cells, mesenchymal cells of bone marrow, adipose tissue, microvascular tissue or other mesenchymal tissue origin, osteoprogenitor cells, bone cells and chondrocytes.

### Claim 36 (depends on 31)

The medium according to claim 31 wherein in said cell culture the SPRF is prepared by a method wherein centrifugation is carried out at 1000 to 2000 g.

### Claim 37 (depends on 31)

The medium of claim 31 wherein
said medium comprises 2-20% (v/v), preferably 5-15% (v/v), highly preferably 8 to 12% (v/v) or about 10% (v/v) SPRF and
wherein said medium comprises besides SPRF no FBS (FCS) and no other serum derived product or supplement and preferably no other growth factors.

### Claim 38 (depends on 37)

The medium of claim 37 wherein
the cell culture medium is a derivative of Dulbecco's modified Eagle's medium (DMEM) which differs from DMEM in that it is supplemented with 2-20% (v/v), preferably 5-15% (v/v), highly preferably with 8 to 12% (v/v) or about 10% (v/v) SPRF and
said medium comprises no other serum derived product or supplement and no other growth factors.
